Ocular Therapeutix, Inc
OCUL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001393434
In the last 90 days, Ocular Therapeutix, Inc insiders filed 0 open-market purchases and 5 sales; 262 institutions reported holding it in 13F filings for Q2 2026, worth $2.04B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $333.1K in total
- 5
- 13F holdersQ2 2026, −5 vs. previous quarter
- 262
- 13F valueReported value at the end of Q2 2026
- $2.04B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding OCUL, Q2 2026
No superinvestor reported holding OCUL at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Ocular Therapeutix, Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 2, 2026 (view filing)4:01 PM ET | Aug 31 | 2 days | Notman DonaldChief Operating Officer | SSale | −1.10K | $10.24 | −$11.3K | −0.3%366.5K after | |
| Aug 26, 2026 (view filing)5:59 PM ET | Aug 24 | 2 days | Kaiser PeterChief Development Officer | SSale | −3.04K | $10.77 | −$32.7K | −1.1%264.4K after | 10b5-1 |
| Aug 26, 2026 (view filing)5:58 PM ET | Aug 24 | 2 days | Nayak SanjayChief Strategy Officer | SSale | −1.90K | $10.78 | −$20.4K | −0.6%326.9K after | 10b5-1 |
| Aug 26, 2026 (view filing)5:57 PM ET | Aug 24 | 2 days | Heier Jeffrey S.Chief Scientific Officer | SSale | −3.30K | $10.78 | −$35.5K | −1.0%318.3K after | 10b5-1 |
| Aug 26, 2026 (view filing)5:56 PM ET | Aug 24 | 2 days | Dugel PravinSee Remarks | SSale | −21.6K | $10.77 | −$233.2K | −0.8%2.53M after | 10b5-1 |
| Jun 5, 2026 (view filing) | Jun 3 | 2 days | Waheed NadiaChief Medical Officer | SSale | −14.8K | $8.27 | −$122.6K | −4.7%300.1K after | 10b5-1 |
| May 28, 2026 (view filing) | May 26 | 2 days | Dugel PravinSee Remarks | SSale | −21.2K | $8.20 | −$173.5K | −0.8%2.60M after | 10b5-1 |
| May 28, 2026 (view filing) | May 26 | 2 days | Kaiser PeterChief Development Officer | SSale | −2.97K | $8.20 | −$24.3K | −1.1%266.1K after | 10b5-1 |
| May 28, 2026 (view filing) | May 26 | 2 days | Heier Jeffrey S.Chief Scientific Officer | SSale | −3.02K | $8.20 | −$24.7K | −0.9%320.4K after | 10b5-1 |
| May 28, 2026 (view filing) | May 26 | 2 days | Nayak SanjayChief Strategy Officer | SSale | −1.86K | $8.20 | −$15.2K | −0.6%328.8K after | 10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Ocular Therapeutix, Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 32,844,043 | $322.5M | 0.01% | +190,279+0.6% | Added |
| Deep Track Capital, LP | 19,686,282 | $193.3M | 2.85% | 00.0% | Unchanged |
| BlackRock, Inc. | 19,376,555 | $190.3M | 0.00% | +3,243,624+20.1% | Added |
| Avoro Capital Advisors LLC | 12,540,000 | $123.1M | 1.11% | +225,000+1.8% | Added |
| Summer Road LLC | 12,208,296 | $119.9M | 74.46% | +328,471+2.8% | Added |
| VR Adviser, LLC | 10,346,926 | $101.6M | 3.08% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 8,832,595 | $86.7M | 0.00% | +113,556+1.3% | Added |
| Price T Rowe Associates Inc | 7,623,533 | $74.9M | 0.01% | +1,726,384+29.3% | Added |
| Logos Global Management LP | 5,300,000 | $52.0M | 2.24% | +1,450,000+37.7% | Added |
| State Street Corp | 5,233,282 | $51.4M | 0.00% | +524,863+11.1% | Added |